Partnerships are also critical. Many small biotechs deploy CROs to assist with trials, and Conga’s platform allows these ...
Currently, seven CAR T-cell therapies 1 and six T-cell engager therapies have been approved by the FDA. 2 Despite these advancements and their clear benefits, immunotherapy-based treatments carry ...
Last week’s top stories explored the push for digital-first clinical data systems, why cybersecurity must be central in CRO qualification, and how AI-driven contracting tools are helping sponsors cut ...
The FDA has approved Eli Lilly’s Inluriyo (imlunestrant), the first oral estrogen receptor antagonist for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, ...
AstraZeneca and Daiichi Sankyo have announced that their supplemental Biologics License Application (sBLA) for Enhertu ...
Tom Cowen, head, healthcare, life sciences, Conga, shares how leading pharmaceutical companies are using Contract Lifecycle ...
The pharmaceutical industry, with its wealth of sensitive data and critical research, must remain at the forefront of cybersecurity efforts. By integrating cybersecurity considerations into every ...
Paul Shawah, EVP, strategy, Veeva Systems and Richard Staub, president, R&D solutions, IQVIA, explain how their partnership ...
Modernizing Clinical Trials: A Site-Centered Roadmap for the Future Simplifying startup, empowering sites through networks, ...
Michel van Harten, MD, CEO, myTomorrows; and Kyle McAllister, co-founder, CEO, Trially, discuss how artificial intelligence ...
Pharma R&D faces rising trial complexity, high costs, and patient and investigator shortages, driving the need for adaptive models and data-driven strategies to speed therapies to market.
An interim analysis of the TULIP-SC trial found that weekly subcutaneous delivery of Saphnelo significantly reduced disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results